Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | F9 | P00740 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22170036 | 0.83 | ALOX5 (0.39) | HPGDTACR3ALOX5CES2CES1 | |
| SCHEMBL3173895 | 0.83 | ALOX5 (0.41) | HPGDALOX5CES2CES1KEAP1 | |
| SCHEMBL2821064 | 0.81 | HPGD (0.45) | HPGDTACR3ALOX5CES2CES1 | |
| SCHEMBL2370589 | 0.80 | HPGD (0.55) | HPGDTACR3ALOX5CES2CES1 | |
| SCHEMBL9000694 | 0.80 | CES2 (0.56) | HPGDTACR3ALOX5CES2CES1 | |
| SCHEMBL12895886 | 0.80 | HPGD (0.55) | HPGDTACR3ALOX5CES2CES1 | |
| SCHEMBL8237520 | 0.80 | HPGD (0.44) | HPGDTACR3ALOX5CES2CES1 | |
| SCHEMBL11666936 | 0.79 | ALOX5 (0.46) | HPGDALOX5CES2CES1KEAP1 | |
| SCHEMBL202116 | 0.79 | ALOX5 (0.46) | HPGDTACR3ALOX5CES2CES1 | |
| SCHEMBL6703331 | 0.79 | HPGD (0.43) | HPGDTACR3ALOX5CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | disclosed |
| EP-1948629-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007053436-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| EP-0623120-A1 | PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014077-A1 | PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
| EP-0045165-B1 | RHODANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION, AND ALDOSE REDUCTASE INHIBITORS CONTAINING SUCH DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1986-03-12 | — | — | EP | disclosed |
| US-4446143-A | Rhodanine derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-05-01 | — | — | US | disclosed |
| EP-0045165-A1 | Rhodanine derivatives, a process for their preparation, and aldose reductase inhibitors containing such derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY5R, NPY4R | HPGD 3636/4885TACR3 485/4885ALOX5 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.